Category - Developments

Developments

Think Research to acquire MDBriefCase Group

Think Research (TSXV:THNK) agreed to acquire closely-held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...

January 20, 2021

Developments

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...

January 15, 2021

Developments

Neuronetics Q4 preliminary revenue tops guidance

Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...

January 13, 2021

Developments

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

Diabeloop and SFC Fluidics agreed to develop a Type 1 diabetes system that integrates SFC’s alternate controller-enabled (ACE) insulin pod into Diabeloop’s automated insulin delivery solution in the U.S. The new...

January 11, 2021

Developments

iBio’s FastPharming featured in Genetic Engineering & Biotechnology News

iBio’s (NYSE American:IBIO) plant-based FastPharming System and customized FastGlycaneering tools were featured in an article in Genetic Engineering & Biotechnology. Sylvain Marcel, Ph.D., VP of protein expression...

January 11, 2021

Developments

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Closely-held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...

January 7, 2021

Developments

IntelGenx receives first purchase order for CBD filmstrips from Heritage Cannabis

IntelGenx (TSXV:IGX; OTCQB:IGXT) executed of a definitive supply agreement with Heritage Cannabis Holdings (CSE:CANN; OTCQX:HERTF) to manufacture and supply filmstrip products containing 10 mg of cannabidiol (CBD) using...

January 7, 2021

Developments

Profound Medical Q4 preliminary revenue beats consensus estimates

Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...

January 6, 2021

Developments

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

aTyr Pharma (NASDAQ:LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do...

January 5, 2021

Developments

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...

December 30, 2020

Category - Developments

Think Research to acquire MDBriefCase Group

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Neuronetics Q4 preliminary revenue tops guidance

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

iBio’s FastPharming featured in Genetic Engineering & Biotechnology News

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

IntelGenx receives first purchase order for CBD filmstrips from Heritage Cannabis

Profound Medical Q4 preliminary revenue beats consensus estimates

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter